On August 27, 2021 Lynk Pharmaceuticals reported that it completed a Series B financing of $50 million to conduct Phase I/II clinical trials of its pipeline products and expand its international business (Press release, Lynk Pharmaceuticals, AUG 27, 2021, View Source [SID1234586971]). Founded in 2018 by veteran drug hunters with experience working for Pfizer, Merck and Johnson & Johnson, Lynk is developing FIC/BIC small molecule drugs for autoimmune diseases, inflammation and cancer. The financing was led by Lilly Asia Ventures, plus New Alliance Capital and Hangzhou HEDA Biological Medicine as co-investors

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!